LDN-27219

Research use only, not for human use.

LDN-27219 is a potent hTGase inhibitor with IC50 of 0.6 uM.

LDN-27219 is a potent hTGase inhibitor with IC50 of 0.6 uM.

LDN-27219 (30 μM; 12 min) promotes the closed conformation of TGase 2 to activates calcium-activated potassium channels in smooth muscle cells.LDN-27219 (30 μM; 20-25 min) increases the response to acetylcholine in phenylephrine-contracted human subcutaneous arteries.

LDN-27219 (0.1-2 mg/kg; i.v. once) affects vivo arterial pressure and shows larger effects on older rats. Animal Model:12 to 14-week-old male Wistar rats Dosage:0.1, 1 and 2 mg/kg Administration:Intravenous injection; 0.1, 1 and 2 mg/kg once Result:Dose-dependently decreased mean arterial pressure of mice.Animal Model:12 to 14- and 35 to 40-week-old male Wistar rats Dosage:0.1, 1 and 2 mg/kg Administration:Intravenous injection; 0.1, 1 and 2 mg/kg once Result:Decreased mean arterial pressure in old group more significant than young group.

——

Others

Other Targets

hTGase

——

——

312946-37-5

408.5

C20H16N4O2S2

>98% (HPLC)

DMSO:122 mg/mL (298.65 mM)

NNC(=O)CSc1nc2scc(-c3ccccc3)c2c(=O)n1-c1ccccc1

——

(-20℃)

With Ice Pack

≥ 2 years